CBIO
Crescent Biopharma, Inc.12.92
-0.29-2.2%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
216.83MP/E (TTM)
-Basic EPS (TTM)
-Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
10-Q
Q2 FY2025 results
Crescent Biopharma posted a $21.8M net loss for Q2 FY2025 ended June 30, 2025, up from a $15.1M loss in Q1 (derived), driven by $12.1M in R&D expenses—mostly Paragon-related work on CR-001, CR-002, and CR-003 programs—and $8.9M in G&A, including $3.6M share-based comp. The net loss exceeded the operating loss by $0.8M due to interest expense on converted notes. Cash swelled to $152.6M after a June reverse recapitalization with GlycoMimetics, yielding $145.4M in financing inflows net of $27.3M operating burn; no debt remains. The merger closed June 13 for stock consideration, recognizing no goodwill. Free cash flow not disclosed in the 10-Q. Competition from established PD-1/VEGF therapies could pressure CR-001's path.
8-K
Q2 loss and severance plan
Crescent Biopharma reported Q2 2025 net loss of $21.8 million, with R&D expenses at $12.1 million and G&A at $8.9 million, while cash stood at $152.6 million to fund operations through 2027. The board approved an Executive Severance Plan on July 29, offering VP-level staff base salary continuation up to 1.0x for qualifying terminations and enhanced 1.5x lump sums plus equity acceleration post-change in control. This bolsters retention amid pipeline advances like CR-001's IND filing. Plan ties benefits to releases and covenants.
IPO
Employees
Sector
Industry
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CLRB
Cellectar Biosciences, Inc.
3.18-0.02
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
CRBP
Corbus Pharmaceuticals Holdings
8.66-0.82
CRBU
Caribou Biosciences, Inc.
1.69-0.02
CUE
Cue Biopharma, Inc.
0.41-0.05
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MBIO
Mustang Bio, Inc.
1.07-0.06
XLO
Xilio Therapeutics, Inc.
0.65+0.00
YDES
YD Bio Limited
12.62+0.22